[
    ">50</sub>mean\u22125.95\u22127.34\u22126.74\u2014\u2014\u2014SEM0.030.140.07\u2014\u2014\u2014N555555G11NorepinephrineDexmedetomidineBrimonidine\u20189087\u20187075PS75Emaxmean10025153&lt;5&lt;5&lt;5SEM3.221.4410.12\u2014\u2014\u2014LogEC<sub>50</sub>mean\u22125.90\u22127.62\u22126.26\u2014\u2014\u2014SEM0.060.140.16\u2014\u2014\u2014N555555G14NorepinephrineDexmedetomidineBrimonidine\u20189087\u20187075PS75Emaxmean10024117&lt;5&lt;5&lt;5SEM3.480.944.06\u2014\u2014\u2014LogEC<sub>50</sub>mean\u22125.83\u22127.64\u22126.77\u2014\u2014\u2014SEM0.060.100.08\u2014\u2014\u2014N555555G15NorepinephrineDexmedetomidineBrimonidine\u20189087\u20187075PS75Emaxmean10074107&lt;5&lt;5&lt;5SEM0.020.020.04\u2014\u2014\u2014LogEC<sub>50</sub>mean\u22126.30\u22127.59\u22127.42\u2014\u2014\u2014SEM0.940.751.65\u2014\u2014\u2014N555555barrestin1NorepinephrineDexmedetomidineBrimonidine\u20189087\u20187075PS75Emaxmean10030103&lt;5&lt;5&lt;5SEM2.841.105.05\u2014\u2014\u2014LogEC<sub>50</sub>mean\u22125.80\u22127.89\u22126.17\u2014\u2014\u2014SEM0.050.090.12\u2014\u2014\u2014N555555barrestin2NorepinephrineDexmedetomidineBrimonidine\u20189087\u20187075PS75Emaxmean1003892&lt;5&lt;5&lt;5SEM1.530.942.58\u2014\u2014\u2014LogEC<sub>50</sub>mean\u22125.94\u22127.62\u22126.74\u2014\u2014\u2014SEM0.020.060.07\u2014\u2014\u2014N555555G-protein and \u03b2-Arrestin signaling for docking compounds in BRET-biosensor based assays in HEK293T cells expressing the human \u03b1<sub>2A</sub>AR. All compound responses normalized to norepinephrine response.<sup>a</sup>Endogenous G<sub>i/o </sub>protein family activation in the absence of heterologously expressed G proteins.\u2014, not determined.</p>TABLE\u20033Binding affinity and functional properties of selected \u20329087 analogs to the human \u03b1<sub>2A</sub>AR receptor.G<sub>i </sub>EC<sub>50 </sub>\u00b1 SE<sup>b</sup>E<sub>max </sub>\u00b1 SEM<sup>b</sup>\u03b2-Arr-2<sup>e</sup>StatisticalMean logEC50 (SEM)<sup>c</sup>EC<sub>50</sub>differencesK<sub>i </sub>(nM)<sup>a</sup>Relative activity<sup>d</sup>E<sub>max</sub>for CompoundnnnG<sub>i </sub>activity<sup>f</sup><img id=\"EMI-C00341\" path=\"US20250032476A1-20250130-C00341.TIF\" file=\"https://surechembl.org/api/assets/attachment/1358089692/US/20250130/A1/020250/03/24/76/US20250032476A1-20250130-C00341.TIF\"/>51 \u00b1 8.8 652 nM \u00b1 24 60% \u00b1 3 \u22127.585 (0.169) 9.354 (0.171) 9\u2003 \u2014nM &lt;5% 6 \u20325879* PS84**** PS86**** PS75** \u20327075**** <img id=\"EMI-C00342\" path=\"US20250032476A1-20250130-C00342.TIF\" file=\"https://surechembl.org/api/assets/attachment/1358089695/US/20250130/A1/020250/03/24/76/US20250032476A1-20250130-C00342.TIF\"/>&gt;10000 3\u2014nM &lt;5% ND ND 4\u2014\u2014 <img id=\"EMI-C00343\" path=\"US20250032476A1-20250130-C00343.TIF\" file=\"https://surechembl.org/api/assets/attachment/1358089698/US/20250130/A1/020250/03/24/76/US20250032476A1-20250130-C00343.TIF\"/>&gt;10000 3\u2014nM 57%\u2003\u00b1\u20039\u2003@\u20030.1\u2003mM ND ND 4\u2014\u2014 <img id=\"EMI-C00344\" path=\"US20250032476A1-20250130-C00344.TIF\" file=\"https://surechembl.org/api/assets/attachment/1358089701/US/20250130/A1/020250/03/24/76/US20250032476A1-20250130-C00344.TIF\"/>4600\u2003\u00b1\u20032100 3\u2014nM &lt;5% ND ND 3\u2014\u2014 <img id=\"EMI-C00345\" path=\"US20250032476A1-20250130-C00345.TIF\" file=\"https://surechembl.org/api/assets/attachment/1358089704/US/20250130/A1/020250/03/24/76/US20250032476A1-20250130-C00345.TIF\"/>22\u2003\u00b1\u20036.7 314\u2003nM\u2003\u00b1\u20034.8 47%\u2003\u00b1\u20032 \u22128.180\u2003(0.296) 9.845\u2003(0.294) 7\u2003 \u2014nM &lt;5% 3\u2003 \u2003 PS84**** PS86**** <img id=\"EMI-C00346\" path=\"US20",
    "0353.TIF\"/>1200\u2003\u00b1\u2003560 33400\u2003nM\u2003\u00b1\u2003940 91%\u2003\u00b1\u200315 \u22125.494\u2003(0.109) 7.442\u2003(0.155) 3\u2014\u20329087**** \u20321718**** \u20324914**** \u20325879**** \u20324825**** PS83**** PS70**** PS71** PS75\u2003**** \u20327075**** <img id=\"EMI-C00354\" path=\"US20250032476A1-20250130-C00354.TIF\" file=\"https://surechembl.org/api/assets/attachment/1358089731/US/20250130/A1/020250/03/24/76/US20250032476A1-20250130-C00354.TIF\"/>1800\u2003\u00b1\u2003730 4\u2014nM 43%\u2003\u00b1\u20034\u2003@\u20030.1\u2003mM ND ND 5\u2014\u2014 <img id=\"EMI-C00355\" path=\"US20250032476A1-20250130-C00355.TIF\" file=\"https://surechembl.org/api/assets/attachment/1358089734/US/20250130/A1/020250/03/24/76/US20250032476A1-20250130-C00355.TIF\"/>6600\u2003\u00b1\u20031800 4\u2014nM &lt;5% ND ND 6\u2014\u2014 <img id=\"EMI-C00356\" path=\"US20250032476A1-20250130-C00356.TIF\" file=\"https://surechembl.org/api/assets/attachment/1358089737/US/20250130/A1/020250/03/24/76/US20250032476A1-20250130-C00356.TIF\"/>8.2\u2003\u00b1\u20030.48 44.8\u2003nM\u2003\u00b1\u20031.3 82%\u2003\u00b1\u20034 \u22128.441\u2003(0.148) 10.352\u2003(0.149) 7\u2003 \u2014nM 15%\u2003\u00b1\u20033\u2003@ 0.1\u2003mM 6\u20329087** PS71*** PS84**** PS86**** <img id=\"EMI-C00357\" path=\"US20250032476A1-20250130-C00357.TIF\" file=\"https://surechembl.org/api/assets/attachment/1358089740/US/20250130/A1/020250/03/24/76/US20250032476A1-20250130-C00357.TIF\"/>37\u2003\u00b1\u20035.1 54.1\u2003nM\u2003\u00b1\u20031.2 93%\u2003\u00b1\u20035.2 \u22128.509\u2003(0.117) 10.471\u2003(0.095) 9\u2003 \u2014nM 10%\u2003\u00b1\u20037@ 0.1\u2003mM 7\u20329087**** PS70** PS71**** PS84**** PS86****<sup>a</sup>Binding affinity to human \u03b1<sub>2A</sub>AR as mean K<sub>i </sub>value in [nM]\u2003\u00b1\u2003SEM. <sup>b</sup>G-protein activation monitored in a BRET-biosensor based assay using the human \u03b1<sub>2A</sub>AR. <sup>c</sup>logEC50 (means calculated from each replicate) of G-protein signaling monitored in a BRET-biosensor based assay using the human \u03b1<sub>2A</sub>AR. <sup>d</sup>Relative activity, log(E<sub>max</sub>/EC<sub>50</sub>), of G-protein signaling monitored in a BRET-biosensor based assay using the human \u03b1<sub>2A</sub>AR. <sup>e</sup>\u03b2-Arrestin-2 recruitment measured with a BRET-biosensor based assay and the human \u03b1<sub>2A</sub>AR. <sup>f</sup>Differences of relative compound activities (log(E<sub>max</sub>/EC<sub>50</sub>) were analyzed by One-way ANOVA applying Tukey\u2032s multiple comparisons test in PRISM 9.3.1. *p &lt;\u20030.05, **p &lt;\u20030.01, ***, p &lt;\u20030.001; ****, p &lt;\u20030.0001. Only compounds with statistically significant differences are listed. \u2014\u2003, not determined.</p>TABLE 4Binding affinity of \u20329087 to other adrenergic receptors.<sup>a</sup>\u03b1<sub>2C</sub>AR\u03b1<sub>1A</sub>AR\u03b1<sub>1B</sub>AR\u03b2<sub>1</sub>AR\u03b2<sub>2</sub>AR0.027 \u00b1 0.004 \u03bcM (3)1.3 \u00b1 0.37 \u03bcM (4)7.4 \u00b1 0.64 \u03bcM (3)&gt;10 \u03bcM (3)&gt;10 \u03bcM (3)<sup>a</sup>Binding affinity to related adrenergic receptors as mean K<sub>i </sub>value in [\u03bcM \u00b1 s.e.m.] each done in triplicates; number of individual experiments are displayed in parentheses.</p>TABLE 5Pharmacokinetic properties of docking agonists.OralPermeabilityCom-RoutesPKbio-predictionpound(dose)parameters<sup>a, b, c</sup>PlasmaBrainCSFavailability<sup>d</sup>(kcal/mol)<sup>e</sup>\u20189087I.P.Cmax14405960447152%<sup>f</sup>\u22122.207(10(ng/ml)110000439000154000mg/kg)AUC0.509.8526.83(ng*mi"
]